Harbir K Juj, | |
209 Martin Luther King Jr Way, Tacoma, WA 98405-4265 | |
(877) 828-4510 | |
(253) 383-6106 |
Full Name | Harbir K Juj |
---|---|
Gender | Female |
Speciality | Pediatrics |
Location | 209 Martin Luther King Jr Way, Tacoma, Washington |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316059439 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | MD60072373 (Washington) | Primary |
Entity Name | Multicare Health System |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
The results of a study presented today at the European League Against Rheumatism Annual Congress showed for the first time that a combination of text messages and individual counselling sessions to motivate patients with Rheumatoid Arthritis (RA) to be more active resulted in improved patient-reported clinical outcomes.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.
Down syndrome, the most common chromosomal disorder in America, can be complicated by significant deterioration in movement, speech and functioning in some adolescents and young adults. Physicians previously attributed this regression to depression or early-onset Alzheimer's, and it has not responded to treatments.
A computational study that analyzes and explores the time-based structures of the SARS-CoV-2 variants with specific spike (S) protein mutations is discussed here.
Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA).
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Harbir K Juj, 209 Martin Luther King Jr Way, Tacoma, WA 98405-4267 Ph: (877) 828-4510 | Harbir K Juj, 209 Martin Luther King Jr Way, Tacoma, WA 98405-4265 Ph: (877) 828-4510 |
News Archive
The results of a study presented today at the European League Against Rheumatism Annual Congress showed for the first time that a combination of text messages and individual counselling sessions to motivate patients with Rheumatoid Arthritis (RA) to be more active resulted in improved patient-reported clinical outcomes.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.
Down syndrome, the most common chromosomal disorder in America, can be complicated by significant deterioration in movement, speech and functioning in some adolescents and young adults. Physicians previously attributed this regression to depression or early-onset Alzheimer's, and it has not responded to treatments.
A computational study that analyzes and explores the time-based structures of the SARS-CoV-2 variants with specific spike (S) protein mutations is discussed here.
Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA).
› Verified 1 days ago
David Lee Robinson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-2252 | |
Nan Shin, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1112 S Cushman Ave, Tacoma, WA 98405 Phone: 253-593-2144 Fax: 253-280-9881 | |
Arthur L Walter, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Pediatric Extended Care Clinic, Madigan Army Medical Center, Tacoma, WA 98431 Phone: 253-968-3066 | |
Bradley Stanton Hood, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 311 S L St, Tacoma, WA 98405 Phone: 253-403-1540 | |
Kirk N. Liesemer, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-3066 | |
Christopher Anthony Bellotti, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 603 S J St Ste 102, Tacoma, WA 98405 Phone: 253-396-4868 Fax: 253-396-4870 | |
Dr. Michael Timothy Alston, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 209 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-596-3300 |